Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

En fas 2-studie av effektivitet och säkerhet av GAL-101, 2 % oftalmisk lösning i icke-foveal geografisk atrofi sekundärt till icke-neovaskulär AMD (eDREAM)

9 november 2026 uppdaterad av: Galimedix Therapeutics Inc

En fas 2, dubbelmaskerad, randomiserad, multicenter, parallell grupp, placebokontrollerad studie för att undersöka effektiviteten och säkerheten av GAL-101, 2 %, oftalmisk lösning hos patienter med icke-foveal geografisk atrofi sekundärt till icke-neovaskulär ålder- relaterad makuladegeneration: EDREAM-studie

Age-related macular degeneration (AMD) affects millions of elderly patients. When advanced, there is Geographic Atrophy (GA) in the retina. This means that there is an area with a loss of light-sensitive cells, called photoreceptors. That part of the retina can no longer see. Atrophy begins as a small spot in the retina distant from the fovea which is the part of the retina responsible for sharp central vision. The GA grows, and when it reaches the fovea, vision is severely diminished, and details cannot be seen anymore. The purpose of the eDREAM study is to understand if GAL-101 can slow the growth of GA and prevent it from reaching the fovea. GAL-101 is given as eyedrops. eDREAM patients will administer study eyedrops every day. Patients will be assigned by chance (randomly) to receive either eye-drops that contain the new medication, GAL-101, or eyedrops without the active drug (Placebo). Neither patients nor doctors will know which treatment was assigned to each patient until the end of the study.

Studieöversikt

Status

Rekrytering

Detaljerad beskrivning

In this study, if both eyes qualify for the study, the eye with the better BCVA will be defined as the study eye. If both eyes qualify for the study and have identical BCVA, then the eye with higher baseline peripheral retinal degenerations (PRD) will be defined as the study eye. If baseline PRD is identical, then the right eye (OD) will be defined as the study eye. Only the study eye will be dosed with the Investigation Medicinal Product (IMP).

During visits, patients will administer 3 applications of 1 drop of GAL-101 or a matching Placebo that does not contain the active pharmaceutical ingredient (API) at 5-minute intervals (i.e., 1st application, wait 5 minutes, 2nd application, wait 5 minutes, 3rd application), under the supervision of trained and authorized study personnel. In between visits, patients will be instructed to administer 2 applications of 1 drop at 5-minute intervals once a day.

The study will be comprised of a 12- to 24-month treatment period determined individually according to patients' overall placement in global study randomization. All patients will participate at least 12 months of treatment. The visit schedule includes the following: Screening visits (Visit 1a and 1b) for image capture and confirmation of study eligibility by a reading center; Baseline/Randomization/Day 1 (Visit 2); a phone call at 2 weeks; and on-treatment clinic visits for safety and efficacy evaluations at 1 month, 3 months, 6 months, 9 months, and 12 months. Patients will continue to attend on-treatment clinic visits at 3-month intervals after 12 months until the last patient randomized in the study has completed 12 months of study treatment.

Studietyp

Interventionell

Inskrivning (Beräknad)

110

Fas

  • Fas 2

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studiekontakt

  • Namn: Galimedix Inc. c/o Imperial CRS, MD
  • Telefonnummer: +1 (301) 9179191
  • E-post: info@galimedix.com

Studera Kontakt Backup

Studieorter

      • Yerevan, Armenien, 0048
        • Rekrytering
        • Ophthalmological Center After S.V. Malayan
        • Kontakt:
        • Huvudutredare:
          • Lilit Voskanyan, MD, PhD
      • Bordeaux, Frankrike, 33000
        • Rekrytering
        • Centre Rétine Gallien
        • Kontakt:
        • Huvudutredare:
          • Eric Fourmaux, MD
      • Lyon, Frankrike, 69317
        • Rekrytering
        • Hopital de La Croix-Rousse Service D'Ophtalmologie Groupement Hospitalier Nord Hospices Civils de Lyon
        • Kontakt:
        • Huvudutredare:
          • Laurent KODJIKIAN, MD
      • Marseille, Frankrike, 13008
        • Rekrytering
        • Centre Monticelli Paradis d'Ophtalmologie
        • Kontakt:
        • Huvudutredare:
          • François Devin, MD
      • Paris, Frankrike, 75006
        • Rekrytering
        • Centre Ophtalmologique Odéon
        • Kontakt:
        • Kontakt:
          • Favard, MD
        • Huvudutredare:
          • Catherine Favard, MD
      • Tours, Frankrike, 37540
        • Rekrytering
        • Centre médico-chirurgical de Touraine
        • Kontakt:
        • Huvudutredare:
          • Sam Razavi, MD
    • California
      • Beverly Hills, California, Förenta staterna, 90211
        • Rekrytering
        • Retina-Vitreous Associates Medical Group
        • Huvudutredare:
          • David Boyer, MD
        • Kontakt:
      • Walnut Creek, California, Förenta staterna, 94598
        • Rekrytering
        • Bay Area Retina Associates
        • Huvudutredare:
          • Roger Goldberg, MD
        • Kontakt:
    • Maryland
      • Hagerstown, Maryland, Förenta staterna, 21740
        • Upphängd
        • Cumberland Valley Retina Consultants
      • Tbilisi, Georgien, 0162
        • Rekrytering
        • Akhali Mzera Limited
        • Kontakt:
        • Huvudutredare:
          • Shalva Skhirtladze, MD
      • Tbilisi, Georgien, 0186
        • Rekrytering
        • Caucasus Medical Centre LLC
        • Kontakt:
        • Huvudutredare:
          • Mikheil Omiadze, MD, PhD
      • Kildare, Irland, W91 W535
        • Rekrytering
        • UPMC Kildare Hospital Prosperous Rd Clane, Kildare Ireland
        • Huvudutredare:
          • Eugene Ng, MD
        • Kontakt:
      • Waterford, Irland, X91 DH9W
        • Rekrytering
        • Institute of Eye Surgery (IOES Waterford)
        • Huvudutredare:
          • Eugene Ng, MD
        • Kontakt:
      • Jerusalem, Israel, 9112001
        • Rekrytering
        • Hadassah Medical Center
        • Kontakt:
        • Huvudutredare:
          • Tareq Jaouni, MD
      • Tel Aviv, Israel, 6423906
        • Rekrytering
        • Tel Aviv Medical Center
        • Kontakt:
        • Huvudutredare:
          • Omer Trivizki, MD
    • Milano
      • Milan, Milano, Italien, 20123
        • Rekrytering
        • Medical Retina & Imaging Unit, IRCCS MultiMedica, Ospedale San Giuseppe
        • Kontakt:
        • Huvudutredare:
          • Stela Vujosevic, MD
      • Milan, Milano, Italien, 20132
        • Rekrytering
        • Unità di Oculistica, IRCCS Ospedale San Raffaele
        • Kontakt:
        • Huvudutredare:
          • Francesco Bandello, MD
    • Roma
      • Roma, Roma, Italien, 00184
        • Rekrytering
        • UOS Retina Medica, P.O. Britannico, IRCCS Fondazione G.B. Bietti per lo Studio e la Ricerca in Oftalmologia
        • Kontakt:
        • Huvudutredare:
          • Mariacristina Parravanno, MD
      • Bonn, Tyskland, 53127
        • Rekrytering
        • Universitäts-Augenklinik Bonn
        • Huvudutredare:
          • Kristina Pfau, MD
        • Kontakt:
      • Freiburg im Breisgau, Tyskland, 79106
        • Rekrytering
        • Universitätsklinikum Freiburg Klinik für Augenheilkunde
        • Huvudutredare:
          • Hansjuergen Agostini, MD
        • Kontakt:
      • Hanover, Tyskland, 30625
      • Neubrandenburg, Tyskland, 17036
        • Rekrytering
        • Dietrich Bonhoeffer Klinikum
        • Kontakt:
        • Huvudutredare:
          • Christian Brinkmann, MD
      • Tübingen, Tyskland, 72076
        • Rekrytering
        • Universitätsklinikum Tübingen, Department für Augenheilkunde.
        • Kontakt:
        • Huvudutredare:
          • Felix Reichel, MD
      • Ulm, Tyskland, 89075
        • Har inte rekryterat ännu
        • UNIVERSITÄTSKLINIKUM ULM Klinik für Augenheilkunde
        • Kontakt:
        • Huvudutredare:
          • Armin Wolf, MD

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

55 år och äldre (Vuxen, Äldre vuxen)

Tar emot friska volontärer

Nej

Kön som är behöriga för studier

Allt

Beskrivning

Inclusion Criteria:

  • ≥55 years of age

  • Willing and able to provide written informed consent

  • Willing and able to comply with the study schedule and study assessments

  • Able to successfully administer ophthalmic solution or have an appropriate designee (e.g., family member, health care professional) who can administer ophthalmic solution

  • BCVA of ≥50 letters in the study eye using Early Treatment Diabetic Retinopathy Study (ETDRS) chart (i.e., 20/100 Snellen equivalent). Criterion will be confirmed at Baseline

  • Refractive error between +3 and -6 diopters spherical equivalent in the study eye

  • Sufficiently clear ocular media and adequate pupillary dilation to permit quality fundus imaging of the study eye, in the opinion of the Investigator. Criterion will be confirmed at Baseline

  • Diagnosed with non-foveal GA secondary to non-neovascular AMD in the study eye, as confirmed by the reading center

    1. Well-delineated cumulative GA area between 1.25 and 12.0 mm2
    2. If GA is multifocal, at least 1 lesion ≥1.25 mm2
    3. GA lesions must be located outside a ≥100 µm radius from the center point of the fovea (i.e., this area must have intact retinal pigment epithelium [RPE] and outer retina)
    4. GA lesions must be located (partially or wholly) within a 2000 µm radius from the center point of the fovea
    5. GA lesions must be completely located within FAF imaging field (field 2 to 30-degree image centered on the fovea). GA lesion borders must be >300 µm from image edges
    6. GA lesions must be >300 µm from the optic disc and/or peripapillary atrophy
    7. Area of PRD must be cumulatively between 7.25 and 25.0 mm2

Exclusion Criteria:

  1. Presence or history of choroidal neovascularization (CNV). Criterion will be confirmed at Baseline

  2. History of laser therapy in the macular region, regardless of indication

  3. History of herpes zoster

  4. Ophthalmic disease or condition that requires or is likely to require surgery during the study period

  5. GA with cumulative area <1.25 mm2

  6. Any GA lesion within 100 µm radius from the center point of the fovea

  7. Axial length >26 mm

  8. Any ocular disease or condition other than non-neovascular AMD that may, in the opinion of the Investigator, interfere with study assessments, patient adherence to the study schedule, or interpretation of study data (e.g., epiretinal membrane, macular hole, glaucomatous optic neuropathy, etc.)

  9. Intraocular surgery (including cataract extraction and crystalline lens replacement) within 3 months before Visit 1a or yttrium aluminum garnet (YAG) surgery within 2 months before Visit 1a, or planned either during the study period

  10. Use of pegcetacoplan or avacincaptad pegol within 6 months before Visit 1a, or planned use during the study period

  11. Use of any prescription or over-the-counter ophthalmic medication within 1 month before Visit 1a or planned use during the study period

  12. Use of rigid contact lenses within 1 month before Visit 1a or planned use during the study period

    Non-study Eye:

  13. BCVA of <5 letters using ETDRS chart (i.e., 20/800 Snellen equivalent)

    Either Eye:

  14. History of uveitis

  15. GA secondary to any condition other than non-neovascular AMD

  16. History of active ocular infection or inflammation within 3 months before Visit 1a or Baseline. Criterion will be confirmed at Baseline

  17. Underwent investigational treatment for AMD within 6 months before Visit 1a

    General Exclusion Criteria:

  18. History of therapeutic radiation to the cranium

  19. Known allergy or hypersensitivity to the investigational medicinal product (IMP) or any of its excipients

  20. History of malignant disease

  21. Use of hydroxychloroquine within 1 month before Visit 1a, or planned use during the study period

  22. Participated or plan to participate in any other IMP study within 1 month before Visit 1a or during the study period

  23. Use of lutein >10 mg per day or zeaxanthin >2 mg per day within 1 month before Visit 1a, or planned use during the study period

  24. Any medical condition (including mental), in the opinion of the Investigator, that could interfere with study assessments, patient adherence to the study schedule, or interpretation of study data

  25. Screening laboratory values, in the opinion of the Investigator, that make the patient unsuitable for study participation

  26. Pregnant, nursing, or planning a pregnancy during the study. Criterion will be confirmed at Baseline

  27. Unwilling or unable to use an acceptable method of contraception throughout the study if a woman of childbearing potential (WOCBP) or if a sexual partner of a WOCBP

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Behandling
  • Tilldelning: Randomiserad
  • Interventionsmodell: Parallellt uppdrag
  • Maskning: Fyrdubbla

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Experimentell: GAL-101 ophthalmic solution

Patient will apply daily 2 eye drops of GAL-101 at 5 minutes interval

Patient will apply daily 2 eye drops of GAL-101 at 5 minutes interval

Placebo-jämförare: Placebo

Patient will apply daily 2 eye drops ofPlacebo at 5 minutes interval

Patient will apply daily 2 eye drops of Placebo at 5 minutes interval

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Efficacy of GAL-101 ophthalmic solution in reducing the rate of change in GA lesion size.
Tidsram: From baseline to last on-treatment visit (48 up to 96 weeks)

Comparison between groups of annual rate of change in the area of GA as measured by fundus autofluorescence (FAF).

From baseline to last on-treatment visit (48 up to 96 weeks)

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Efficacy of GAL-101 ophthalmic solution in reducing the rate of change in photoreceptor degeneration (PRD) in eyes with GA
Tidsram: From baseline to last on-treatment visit (48 up to 96 weeks)

Comparison between groups of annual rate of change in the area of PRD as measured by optical coherence tomography (OCT)

From baseline to last on-treatment visit (48 up to 96 weeks)

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Faktisk)

10 januari 2025

Primärt slutförande (Beräknad)

30 mars 2028

Avslutad studie (Beräknad)

30 maj 2028

Studieregistreringsdatum

Först inskickad

23 oktober 2024

Först inskickad som uppfyllde QC-kriterierna

24 oktober 2024

Första postat (Faktisk)

26 oktober 2024

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

10 november 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

9 november 2026

Senast verifierad

1 november 2026

Mer information

Termer relaterade till denna studie

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

OBESLUTSAM

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Ja

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera